About OncoGenex



OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer

Friday, Jan 16 2015

OncoGenex to Regain Rights to Custirsen from Teva

Tuesday, Dec 30 2014

OncoGenex Announces Results from the Phase 2 Borealis-1™ Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer

Friday, Dec 19 2014

OncoGenex Announces Completion of Patient Enrollment in the Rainier™ Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

Tuesday, Dec 16 2014

OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference

Monday, Nov 17 2014

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014

Thursday, Oct 30 2014

OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014

Thursday, Oct 16 2014


External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue